Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis

Abstract

Background and purposeThe predictive role of modified Glasgow prognostic score (mGPS) for long-term survival in several types of cancers has been well manifested. We supposed that preoperative mGPS might also be associated with long-term survival of operated non-small cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to identify the prognostic value of preoperative mGPS in surgical NSCLC patients.MethodsThe PubMed, Web of Science, EMBASE and CNKI databases were searched for relevant studies up to November 7, 2022. The primary and secondary outcomes were overall survival (OS) and disease-free survival (DFS), respectively. The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined.ResultsA total of 3,803 patients from 11 studies were enrolled and analyzed. The combined results demonstrated elevated preoperative mGPS was significantly related to poorer OS (HR = 2.11, 95% CI: 1.83–2.44, P < 0.001) and DFS (HR = 1.70, 95% CI: 1.42–2.03, P < 0.001). Subgroup analysis for the OS further identified the predictive role of elevated preoperative mGPS for worse OS in NSCLC.ConclusionPreoperative mGPS was significantly associated with prognosis in NSCLC and patients with elevated preoperative mGPS experienced poorer long-term survival.

Prognostic value of perioperative changes in the prognostic nutritional index in patients with surgically resected non-small cell lung cancer

“…Further validation studies are needed to establish the reliable cut-off value of PNI ratio. Second, we did not assess other immunonutritional statuses such as the Controlling Nutritional Status (CONUT) score or the Glasgow Prognostic Score (GPS), which have been reported as prognostic factors in patients with NSCLC undergoing surgical resection [27,28]. However, direct comparison of the perioperative changes in the PNI, CONUT score, and GPS is challenging because the nature of each of these variables is different.…”

Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis

“…[ 23 ] Meanwhile, the other meta-analysis by Yang et al just focused on NSCLC patients. [ 52 ] Due to the substantial differences in disease biological characteristics and malignant risk between SCLC and NSCLC, we believe that it is necessary to further identify prognostic value of pretreatment mGPS in SCLC, which contributes to the risk evaluation for SCLC patients. Notably, the study by Mao et al reported an opposite association between elevated mGPS and poor OS in the multivariate analysis combining the distance metastasis and mGPS.…”

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT

“…mGPS, which has been shown to predict poor prognosis in solid cancers, may be suitable for use in elderly cancer patients as it is also an indicator of inflammation and malnutrition associated with immunosenescence [25,26]. Recently, preoperative mGPS has been reported to be a novel and reliable predictor for overall survival and disease-free survival in surgical non-small cell lung cancer [18]. A meta-analysis of 41 clinical trials involving 18348 patients with gastric cancer found that higher mGPS was associated with poorer overall survival [27].…”

“…Despite all these prognostic indicators, novel markers are needed as the response to treatment and clinical course of patients differ. Recently, the modified Glasgow prognostic score (mGPS) in cancer patients has been used as a new indicator to determine the prognosis and survival of patients [16][17][18]. The prognostic value of mGPS was also confirmed in gastric cancer.…”